Body of Proof
Biomonitoring Data Reveal Widespread Bisphenol A Exposures

A review of more than 80 biomonitoring studies from nine nations suggests exposure to bisphenol A (BPA) is ubiquitous in people throughout the world [EHP 118(8):1055–1070; Vandenberg et al.]. Moreover, in samples of blood serum, median levels of unconjugated (biologically active) BPA were higher than levels predicted by toxicokinetic models that form the basis of U.S. regulations for the compound, reaching the range that has been shown to cause adverse effects in animals.

More than 8 billion pounds of BPA are produced each year, making it one of the world’s most heavily used chemicals. BPA is used in baby bottles, drinking bottles, food storage containers, polycarbonate, stretch films, paper, cardboard, medical equipment, and the epoxy resins lining most metallic food and beverage cans. BPA has estrogenic properties, and animal studies have linked low-level exposure to altered development of the male and female reproductive tract and brain as well as cancers of the mammary gland and prostate.

The authors analyzed 24 biomonitoring studies involving blood serum samples from healthy adults, adults with certain diseases, pregnant women, and fetuses or fetal tissues. Overall, these studies indicate exposure to unconjugated BPA is in the range of 0.5–10 ng/mL, with most studies suggesting an average exposure of 1–3 ng/mL. The latter concentrations are higher than those shown to cause effects in human and animal cell cultures.

Bringing the Bugs Back In
Environmental Health Research Model Combines Toxicology and Infectious Disease

Although pathogens are known to modify the effects of toxicants, U.S. environmental health research currently focuses on physical agents and chemical toxicants—a focus that limits the field by ignoring the interaction between pathogens and toxic agents [EHP 118(8):1165–1172; Feingold et al.]. These authors present a conceptual paradigm that integrates infectious disease and toxicologic environmental health research, promotes cross-disciplinary education and communication, and elucidates a fuller body of environmental health risk factors.

Chemical toxicity often involves relatively direct effects of exposures on health outcomes, but infectious disease transmission typically is more complex, depending on factors such as dynamic environmental and ecological systems, patterns of contact among populations, and host immune status. But interactions between pathogens and toxicants are undeniable. For instance, hepatitis B virus and aflatoxin individually increase the risk of liver cancer, but combined exposure to both agents increases risk far more than would be expected based on effects of the two risk factors in isolation. And in the case of cervical cancer, although infection with human papillomavirus is believed to be necessary for the cancer to occur, smoking may act as a cofactor and increase the risk the cancer will occur in someone infected with the virus.

The authors identify multiple points between initial exposure and clinical disease at which toxicant–pathogen interactions can occur. They also describe approaches common to both areas of research. Both focus on clinical disease at which toxicant–pathogen interactions can occur. They both use biomarkers to study exposure to BPA, which makes it impossible to predict toxicokinetics. Because the biomonitoring findings contradict the toxicokinetic studies, the authors recommend in a related commentary in the same issue [EHP 118(8):1051–1054; Vandenberg et al.] that biomonitoring data be considered in regulatory decision making whenever available rather than relying only on toxicokinetic models to estimate exposure.

The only data on BPA levels in children after birth is from studies of urine samples, most of which measured total (conjugated and unconjugated) BPA, but some of which measured unconjugated BPA separately from conjugated (inactive) BPA. The Centers for Disease Control and Prevention measured total BPA in urine samples from 314 children aged 6–11 years and 715 adolescents aged 12–19. Compared with adults, the younger children’s levels were highest, and adolescents were in-between. Other smaller studies also showed that BPA concentrations were higher in neonates and young children than in adults.

Some of the studies measuring BPA in human blood were conducted using the enzyme-linked immunosorbent assay. Although this assay is considered less specific than the more precise analytical chemistry methods now favored for measuring BPA, the authors argue these studies are worthy of inclusion in their review because the concentrations they report are in line with what have been detected using the newer methods.

The paper also points out “significant deficiencies” in the two studies that have examined the toxicokinetics of BPA exposure in humans, which they say have been given undue weight in regulatory decision making. The authors note we don’t yet know all the potential sources of exposure to BPA, which makes it impossible to predict toxicokinetics. Because the biomonitoring findings contradict the toxicokinetic studies, the authors recommend in a related commentary in the same issue [EHP 118(8):1051–1054; Vandenberg et al.] that biomonitoring data be considered in regulatory decision making whenever available rather than relying only on toxicokinetic models to estimate exposure.

Kellyn S. Betts has written about environmental contaminants, hazards, and technology for solving environmental problems for publications including EHP and Environmental Science & Technology for more than a dozen years.